The clinical impact of Nintedanib and Pirfenidone on pulmonary circulation of interstitial pneumonia: A Hyogo-IP multicenter prospective observational study
Not Applicable
Recruiting
- Conditions
- Interstitial pneumonia
- Registration Number
- JPRN-UMIN000043384
- Lead Sponsor
- Shinko Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who refuse to participate in this study. (2) Patient whose clinician considered inappropriate for this study for any other reasons.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tricuspid regurgitation pressure gradient (TRPG) in patients treated with or without antifibrotics on the 12th month.
- Secondary Outcome Measures
Name Time Method Pulmonary vascular resistance (PVR) in patients treated with or without antifibrotics on the 12th month. To identify the risk factors for pulmonary hypertension.